This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Gastrinoma is a rare type of tumor that originates in the cells of the stomach and small intestine. It is also known as a gastric neuroendocrine tumor (GNET). Gastrinomas are caused by the overproduction of the hormone gastrin. Gastrin is a hormone that is produced in the stomach and stimulates the production of acid, which helps to break down food. When too much of this hormone is produced, it can lead to an increase in the production of acid in the stomach, resulting in a condition known as Zollinger-Ellison Syndrome. Symptoms of gastrinoma may include abdominal pain, nausea, vomiting, diarrhea, and weight loss. Other symptoms may include steatorrhea, which is the presence of fatty stools, and jaundice. In some cases, patients may also experience flushing of the skin, severe headaches, and an enlarged liver. Treatment of gastrinoma typically involves surgery to remove the tumor and any associated tissue. Depending on the size and location of the tumor, chemotherapy, radiation therapy, and/or targeted drug therapy may be used to destroy the tumor or to shrink it. In some cases, medications may be used to block the production of gastrin or to control the symptoms of the condition. Gastrinoma is a rare condition, and it is important to seek medical attention if any of the above symptoms are present. Early diagnosis and treatment is key to managing the condition and preventing any complications that may arise. If left untreated, the condition can cause more serious health problems, including ulcers and bleeding in the digestive tract.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States